Cyclic nucleotide phosphodiesterases (PDEs)a re al arge family of enzymes able to catalyze the hydrolysis of second messengers cAMP and cGMP into the corresponding 5'-nucleotide monophosphates. To date, eleven PDE sub-families (further divided in more than 60 isoforms and splice variants) have been classifiedo nt he basis of their variable tissue localization, kinetic profile, structure similarity,regulation mechanism and differentp harmacological effects explained by their inhibitors. [1, 2] In particular, the PDE4 family actss electively on cAMP and displays ac omplexl ocalization. Indeed, they are mainly found in inflammatory cells, brain, smooth muscle and cardiovascular tissue both at cytosolic and plasmatic membrane level. [3, 4] Within the PDE4 subfamily,f our members have been identified( namely A, B, Ca nd D), further classified in 25 subtypes. All of them can also be distinguished in "long", "short" and "super-short" forms, on the basis of the socalled up-stream conservedr egions( UCRs). [3] [4] [5] [6] [7] In particular, the long isoforms are characterized by two regulatory domains (UCR1 and UCR2), inserted betweent he N-terminal portion and the catalytic domain;i nt he short forms UCR1 domain is missing,w hereas the super-shortf orms lack UCR1 and aUCR2 portion.
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Cyclic nucleotide phosphodiesterases (PDEs)a re al arge family of enzymes able to catalyze the hydrolysis of second messengers cAMP and cGMP into the corresponding 5'-nucleotide monophosphates. To date, eleven PDE sub-families (further divided in more than 60 isoforms and splice variants) have been classifiedo nt he basis of their variable tissue localization, kinetic profile, structure similarity,regulation mechanism and differentp harmacological effects explained by their inhibitors. [1, 2] In particular, the PDE4 family actss electively on cAMP and displays ac omplexl ocalization. Indeed, they are mainly found in inflammatory cells, brain, smooth muscle and cardiovascular tissue both at cytosolic and plasmatic membrane level. [3, 4] Within the PDE4 subfamily,f our members have been identified( namely A, B, Ca nd D), further classified in 25 subtypes. All of them can also be distinguished in "long", "short" and "super-short" forms, on the basis of the socalled up-stream conservedr egions( UCRs). [3] [4] [5] [6] [7] In particular, the long isoforms are characterized by two regulatory domains (UCR1 and UCR2), inserted betweent he N-terminal portion and the catalytic domain;i nt he short forms UCR1 domain is missing,w hereas the super-shortf orms lack UCR1 and aUCR2 portion.
Twop ivotala ctions have beene videnced for UCR1 and UCR2 domains. Firstly,t hey promote the long forms dimerization in vivo,i nvolvingp articularly the UCR1/catalytic domain interfaces. [8] [9] [10] [11] [12] On the other hand, UCR2, closing across the active site, blocks the access to cAMP,t hus exerting ap artial enzyme inhibition. [12, 13] Concerning the active site of PDE4, it shows a7 8% of similarity among the four isoformsa nd it is formedb y three main pockets:ametal pocket( Mp ocket) in which the two catalytic ions (Mg 2 + and Zn 2 + )w ere placed, surrounded by as hell of coordinating-waters, as olvent filled side pocket (S pocket) and an hydrophobic pocket. In that Abstract:A lzheimer'sd isease has recently emerged as ap ossible field of application for PDE4Di nhibitors (PDE4DIs). The great structure similarity among the various PDE4 isoformsa nd, furthermore, the lack of the full length crystal structure of the enzyme, impaired the rational design of new selective PDE4DIs. In this paper,w ith the aim of exploring new insights into the PDE4D binding, we tackled the problemb yp erforming ac omputational study based on docking simulations combinedwith molecular dynamics (D-MD). Our work uniquely identified the binding mode and the key residues involved in the interaction with an umber of in-house catecholi minoether derivatives, acting as PDE4DIs. Moreover,t he new binding mode was tested using as eries of analogues previously reported by us and it was used to confirm their key structural features to allow PDE4Di nhibition. The bindingm odel disclosed within the current computational studym ay prove to be useful to further advance the design and synthesis of novel, more potent and selecregion (Q pocket) the natural substrate engagesabi-dentate H-bond with an invariant glutamine residue (Q369 in PDE4D) whose carbonyl oxygen makes an additional Hbond with ac onserved tyrosine residue (Y329i n PDE4D). [14, 15] PDE4i nhibition has beene xtensively studied, on account of the associated potential therapeutic application. Indeed, PDE4 inhibitors (PDE4Is) may be useful in the treatment of inflammatory diseases, in caseo fb oth respiratory disorders (COPD, asthma) and autoimmunep athologies (rheumatoid arthritis, multiple sclerosis,a topic dermatitis). [15] [16] [17] [18] In addition, PDE4Is displayed positive effects on CNS disorders. [19, 20] In particular,s everal studies indicated the PDE4D isoforms as an interesting target for neurodegenerative pathologies such as Alzheimer'sD isease (AD). [21] Up to now,t he most exploiteds trategy to target PDE4 was to design competitive inhibitorso fc AMP.T hose compounds were active-site-directed and the key-interactions with the enzyme always included an H-bond with Q369 and, usually,t he coordination to the catalytic metal ions in the active site. [22] Twoo ft hem,R oflumilasta nd Apremilast have been recently approved as drug for COPD and psoriatic arthritis treatment, respectively. [23, 24] However,m any studies haveb een recently focused on the role of UCR1-UCR2 oligomers and also of the Cterminal helix conserved region 3( CR3) as negative regulatory domains. Gurneya nd co-workers reported that proper modulators may promote the closure of both UCR2 and CR3 across the active site, explaining in this way the mechanism of inhibition for the PDE4. [25] An ew pattern of interactions has been described for those allosteric modulators:w hile still engaging the H-bond with Q369, they push am oiety out of the active site to interact with eitherU CR2 or CR3 helix rather than showing interactions with the two metal ions of the catalytic pocket. Notably,b oth UCR2 and CR3 display differencesi ns equence between PDE4B and PDE4D isoforms. This fact can be exploitedf or the designo fi soform-selective inhibitors. [25, 26] In the last ten years, our researcho nP DE4Is ledt on umerous Rolipram-related small molecules endowed with as elective inhibition of PDE4D isoform. [27] [28] [29] Compound GEBR-7b (1,T able 1), selected among them for behavioral studies, improved spatial memory both in wild type mice or rats and in the APPswe/PS1dE9 mouse model of AD. [30, 31] In addition,i nt he xylazine/ketamine test and taster eactivity test (two well-knowna ssays used as surrogatem easures of emesis in non-vomiting species) 1 did not induce emesis at doses up to 33-100t imes highert han the pro-cognitive dose. [30] Moreover there is clear evidence that selective PDE4D inhibitors could improve memory without undesirable side effects. [32] Thus, due to these promising results, we werei nterested in the development of our PDE4DIs compound library.P reliminary computational studiesp erformed by us on this PDE4DIs series did not seemt og ive an accurate picture of the ligand-enzyme interaction, not affording areliable model to guide the further synthesis. [28, 29] On this basis, with the aim to more precisely analyze this interaction and clarify the activity of our compound library, ac omputational protocol consisting of docking and molecular dynamics (MD) simulations has been applied. In details, ar e-docking and further dockings with ac ollected database of PDE4DIs, includings ome 3-cyclopentyloxy-4-methoxyphenyl derivatives (compounds 1-5,T able 1), [28] an umber of pyridofuropyrimidines( compounds 6-18, Ta ble 2), [33] and quinolines (compounds 19-35,T able 3), [34] have been performed to set and validate the docking protocol. Subsequently,t wo bindingp oses selected within this first phasewere furtherinvestigated by means of MD. Finally,a dditional docking studies, performed on an externald ataset of our structurallyr elated inhibitors [29] highlighted the potentiality of the selected binding mode in supporting SAR considerations and disclosed the key elements for the furtherd esign of new inhibitors. The first dataseto ft hirty-five PDE4D inhibitors was collected from literature and consisted of five 3-cyclopentyloxy-4-methoxyphenyliminoetherd erivatives( 1-5) [28] (compounds on which the studies were focused) ,t hirteenp yridofuropyrimidines (6-18) [33] and seventeen quinoline compounds (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) [34] .I tw as used for the validationo ft he docking protocol. The second one, instead, was composed by already reported PDE4D inhibitors, [28] analogues of 1-5,e xploited to test the optimizedb inding mode retrieved by MD.
SPECIAL ISSUE
All the compoundsw ere built, parameterized (GasteigerHückelm ethod) and energy minimized within OpenEye Scientific Software [41] using MMFF94s forcef ield. As regarding the protein, five humanP DE4D X-rays out of the thirty-two deposited were collectedf rom Protein Data Bank. [43] Mutateds tructuresa nd low resolutions tructures were discarded. Sincem olecular dynamic simulations were going to be exploitedd uring our workflow,f ragmented crystal structures (evenw hen the portion was ap ivotal regulatory domain) were not selected. Only crystal structures not displaying missing residues in the binding site of PDE4Is were considered. PDE4D X-ray complexess elected for the computational studiesw ere:1 XOQ, [14] 1Y2E, [35] 3IAK, [36] 1OYN, [37] and 1MKD. [38] These X-rays displayed ar ange of resolutionf rom 1.83 to 2.90 and av arious number of inner shield metal-coordinating waters (from 1t o6 ). For all calculations only one molecular chain (chain A) was kepta nd hydrogen atoms were added at an eutral pH.
Docking Studies
The validation of the docking protocol included re-docking calculation and docking experiments of as uitable ligand dataset, followingt he standard procedure. For all the five PDE4D-inhibitorc omplexes, re-docking studies of the corresponding co-crystallized ligandsi nside their own X-ray active site have beenp erformedu sing both AutoDock4.0 [42] and MOE softwares. [43] In particular, the docking protocol was considered successful if the RMSD between the optimum retrieved solution and the crystal pose proved to be smallert han 2.0 .S uccessively,t he database including all the thirty-five compounds, was submitted to docking procedure, that consisted of docking all compounds into the previous five X-rays using AutoDock4.0.
Dockingw as performed to allow flexibility of the ligand but ar igid body protein approximation was used to speed up the calculation. Water molecules were considered fixed in the active site. The simulation used as maller grid, focused on the binding region to predict the binding mode of the ligand dataset. In particular,a ffinity mapsf or all the atom types present, as well as an electrostatic map,w ere SPECIAL ISSUE According to the results of these simulations, two parameters were set for the further calculations:t he crystal to be used and the number of coordinated waters to the metal ions. Calculations werep erformed using computing clusters, and the Grid computing infrastructure. Docking simulation was carried out on the European grid computingi nfrastructure (European Grid Infrastructure( EGI) http:// www.egi.eu/), using an in-house developed software for computation managementi nE GI. The software uses ap ilot job strategyt oa llocate workers on the Grid infrastructure, and then allows an easy jobs ubmission, detection and automatic managemento fG rid failures, job scheduling,a nd near to-constant throughput throughout the docking computation. Sucha pproach allows to tackle large computations reliably on the Grid infrastructure and with highly predictable completiontimes.
As regarding the in silico model validation step, the twelve ligands weredocked in the optimized PDE4D-1 complex structure retrieved from the MD run. More in details the averages tructure of the complex wasc alculated from the MD trajectories by AmberT ools, considering only the frames where the RMSD of the complex was stable. Then, taking that structure as reference, the MD trajectory was analyzed to retrievet he frame with the lower RMSD and this latter was extracted as PDB file. The exploitedd ocking protocol was thesame described above.
PCA Analysis
Given the high amount of data generated by cross-docking experiments, the results were analyzed by means of aPrincipal Component Analysis (PCA)p erformed with the Rs oftware. [44] PCA allow reducing the dimensionality of the original data matrix into as mall number of orthogonal principal components( PC). The result of this process is to map samples through scores and variables by the loadings in an ew vector spaced efined by the relevant principal components (PC). In our particular case as ingle PCA analysis was performed for each inhibitor,c onsidering the crystals tructures as the samples and the number and type of interactions between the ligands and the amino acid residues as the independent variable.P C1 and PC2 resulted to be enough to explain from 60 to 70 %o ft he totalv ariance of the data and were used to draw the further score plots. The preliminary analysis of the score plotsw ell explainedt he effect of the different crystals tructures on the retrieved docking results.
Molecular DynamicSimulations
Molecular dynamic simulations of the complex PDE4D-inhibitor were performed using AMBER12 package [45, 46] starting the experiments from the docking solutions in order to assess their stability along the trajectories. The ligands were parameterized using the semiempirical quantum chemistry methodA M1-BCC to derive partial charges, while the otherc onstants wered erived byt he Antechamber module for the GAFF force field. [47, 48] The protein was parametrized with the AMBER ff03 force field.M g 2 + and Zn 2 + ions weret reateda ccordingt ot he "non-bonded"m odel method. [49] In order to remove all the possible bad contacts betweena toms, preliminarym inimization in vacuum of the system was run using as teepest descendenta lgorithm until energy convergence of 0.0001kcal/mol. The inhibitorprotein complex was solvated in at runcated octahedral periodic box with 8 of perimetral solvent thickness using TIP3P water model. Na + ions were added to neutralize the whole system.
The simulations were performed at neutralp H, with histidines 164 and 200 protonated at d position to coordinate the Zn 2 + ion. The water molecule between the two ions was treated as hydroxidei on as suggested by studies of Li et al., [50] and by MD simulations studies on PDE11p erformed by some of us. [51] Since HIS 160, closet ot he hydroxide ion, can readily capture ap roton, it was protonated at both d and e positions.A ll the bonds involving hydrogen atoms were constrained by the SHAKE algorithm, [52] and the time step was set to 2f s. The non-bonded cutoff distance was8 and long range electrostatic interactions were calculated using the Particle Mesh Ewald (PME) method. Four steps of minimizationw ere performed keeping the position of protein and ligand restrained for four minimizations teps, by af orce constanto f5 00 kcal/mol/ 2 , 100 kcal/mol/ 2 in the second, 10 kcal/mol/ 2 in the third and without ligand and protein restrained in the fourth. All the minimizations teps were run till the system energyc onvergence of 0.0001 kcal/mol. Next the system was heated from 0t o1 00 Ki n3 0psu sing Langevin dynamics at constant volume, and from 100 to 300 Ki n2 0psa tc onstant pressure. After that, the system was equilibratedf or 7nsa t constant pressure of 1atm. Position restrains of 10 kcal/ mol/ were used on the ligand and protein during heating and equilibration steps. After equilibration, productionm olecular dynamics phase was performed at 300 Ku sing constant pressure of 1atm. The exploitedm ethod was validated performing a2 0nsM Ds imulation of the complex 1XOQ-Roflumilast. Then 80 ns MD run were performed for the docking complexes. The resulting trajectories were analyzed using Amber To ols and VMD programs. The root mean square deviation (RMSD) was calculatedf or the protein backbone and ligand atoms using least-squares fitting. The pmemdC UDA program of the AMBER12 package [45] was used for MD simulations running on ac luster Te sla K20 Graphical Processing Unit (GPU).
3Results and Discussion

Docking Protocol Setting
The docking protocol was initially validated by re-docking five co-crystallized ligands (Figure 1 ) in their crystal structure (1XOQ, [14] 1Y2E, [35] 3IAK, [36] 1OYN, [37] and 1MKD, [38] ). For the selection of these five PDE4D X-rays,afirst filter on the thirty-two X-Ray structures of PDE4D deposited into PDB was applied, discarding those structures which gaps in their sequence, mutated residues in the bindingp ocket of the ligands, brokenf ragments (to allow the following MD studies).T hen, according to the structure of our compounds, all characterized by ac atechol moiety,o nly the PDE4s co-crystallized with ac atecholl igand were kept. The final four crystal structures (1MKD, 1OYN,1 XOQ,3 IAK) were selected considering in particular three factors:i )t he inclusion of the metal-coordinating waters in the enzyme 3D model during the calculations;ii) the number of these coordinated waters;i ii)t he resolution of the crystal structures (Table 4) . Finally,o ne extra Xr ay complex,s olved with an ot-catechol ligand was added (1Y2E), to verify if the PDE4 enzymatic pocketd imensions and side-chaind isposition was conditioned by the co-crystallized ligand.
The goodness of this process wase valuated by the root mean square deviation value (RMSD) between the best docking solution (using the most populated cluster within 0.5 kcal/mol from best energyp ose) and the crystal pose: the threshold value wass et to 2.0 ,a ccording to the commond ocking validation protocols. [39] As reported in Ta ble 4, the inclusion of the six coordinated waters during the calculation reduced the RMSD substantially,s uggesting their pivotal role in the interaction between the ligands and the enzyme model.
In particular 1XOQ displayedt he lower RMSD (RMSD = 0.73 )a sw ell as the lower resolution (R = 1.8 ). Consistent results were obtained by docking ad ataseto f3 5 PDE4DIs (compound 1-35,T ables 1-3 and Ta ble 1S in the SupplementaryI nformation Section) into the aforementioned five X-rays structures and analyzing the results by Principal Component Analysis( PCA). In more details, aP CA for each compoundw as performed, taking the crystal structures as the samples. For each amino acid residue, the number and type of interactions engaged with the best pose (in termso fe nergy) of each dockings olutionc luster was calculated. Then, since the number of clusters was different amongt he compounds, the data were expressed as percentage, in order to be used as independent variable in the following analysis..Ascore plot was then produced, displaying ac ommon trend for all the PDE4DIs of the dataset:1 Y2E was not related to the other X-rays, being significantly far from the other objects in the score plot space. Notably it was the only crystal structure with an on-catechol ligand (Figure 1) , thus revealing the effect of the cocrystallized ligand chemotype in the PDE4 docking results. The difference between 1XOQ, 3IAK and 1OYNa nd 1MKD interaction pattern (Figure 2 ) could be associated with the different number of coordinated waters in the active site, in accordance with re-docking calculations (for ligands 6-18, SPECIAL ISSUE Figure 2B , the effect is less important, probably because they less interacted with the Mp ocketw here water molecules are placed, see docking results below).A sr egards 1Y2E, not grouped with the otherX -rays, it was the only crystal structure with an on-catechol ligand (Figure 1 ), thus suggesting to consider even the co-crystallized ligand chemotype during the set-up of PDE4 docking calculations. Ta king together,t he results highlighted the X-ray resolution, the numbero fc oordinated waters and the co-crystal ligand chemotypea st he key factors to be considered for the selection of the best crystal. Consequently,d ocking studies and PCA analysis converged in suggesting 1XOQ as the most suitable model for our further simulations with the catechold erivative dataset of interest (RMSD:0 .73 ,R: 1.8 ,n umber of coordinated waters:6 ,l igand:R oflumilast).
Docking Results
Regardingp yridofuropyrimidine and quinoline scaffolds (compounds 6-18 and 19-35 respectively), only ap reliminary discussion about the docking results was reported, sinced ocking protocol was properly set up for the catechol derivatives. Eachs eries displayedacommons ingle binding posei nto PDE4a ctives ite. For the firstg roup of compounds (6-18,T able 2), the nitrogen atom of the pyridine ring and the oxygen atomofthe furan portion are engaged in ab i-dentate H-bond with Q369 ( Figure 3A) . The different heterocycles at the R 2 position extended their scaffold through the active site, towards the solvent, while the amine substituents at R 1 interacted with Qp ocket residues (Y159, N321, Y329,a nd T333). An additional H-bond between the nitrogen atom in the R 3 chain and the backbone oxygen of S368 was observed for the most potent compounds 15 and 18.
The quinoline derivatives 19-35 (Table 3) engaged an Hbond with Q369 involving the heterocyclicn itrogen atom, while the aryloxy substituents in position 6w ere oriented towardst he Ma nd Sp ockets ( Figure 3B ). The most active compoundsi nt his seriesf ormed additional H-bondsw ith the backbone of N209 and the side chain nitrogen of H204, two residues that in crystals tructuresa re often involvedi n water mediated H-bondsw ith the solvation shell of the two metal ions. More detailed information may be extracted by fine tuning the docking protocol for these two PDE4-Is series, but the descriptionl ied beyond the aim of the presentw ork.
Concerning compounds 1-5 (Table 1 ) the dockings imulations afforded two binding poses within PDE4D active site, namely conformation Aand B. They were characterized by similare nergy and for some of them by similar cluster population distribution (Table 5 ), but displaying different pattern of interaction with the enzyme model:r egarding conformation A ( Figure 3C ), the two catecholo xygen atoms engaged ab i-dentate H-bond with Q369, placing the aromatic ring into an hydrophobic clampm ade of I336 and F372 [14] in order to engage a pÀp interaction with the latter phenylalanine. The rest of the molecule extended inside the active site to make additional interactions with the metal binding pocket. Conformation Bf orm again an H-bond with Q369 this time involving the iminoether oxygen or nitrogen of the structure:a sar esult the aromat-SPECIAL ISSUE Figure 2 . The score plot of compound 1, 15 and 34 (A, B, C, respectively) from the PCA analysis. In the axis the first two components are represented, explaining 68 %, 69 %a nd 62 %o ft he total variance of the system respectively.T he red circle included the clustered objects in the space, while the other ungrouped objects are considered not correlated to the first group. ic ring was placed outside the active site, while the terminal cyclic amine of the structure did not reacht he M pocket of the active site. Relyingo nt he reported experimentald ata about catechold erivatives binding mode within PDE4 actives ite (e.g. Roflumilast in 1XOQ, Rolipram in 1OYN, Zardaverine in 1MKD,P apaverine in 3IAK), conformation Aw as initially selected by us as the commonb inding modef or all these inhibitors, deservingf urther and deeper evaluations on both binding modesb ym eans of MD. Accordingly with our previous calculations, [28] the dockingp oses of compounds 1 and 3 highlighted the presence of further H-bonds with H160 and H204. Concerning compound 2 an additional H-bond was displayed between the morpholineo xygen and the backbone nitrogen of N209. For compounds 4 and 5,i somers R and S showed as imilar behavior within PDE4D active site:p olar interactions were detected betweent he morpholine or dimethylmorpholine oxygena nd the side chains of Q343 (see Ta ble 1S) .
In summary,a ssuming conformation Aa st he proper one for catechol series, docking results suggestedt he key role of additional H-bond with the Mp ocket (in particular with H160 and H204)t oa fford ap roper potency of inhibition of the target.
Since key prerequisite for successful differentiation between active and non-active ligands is the accurate prediction of their binding affinities, MD were subsequently applied. In fact, manys tudies havea lready shown rather poor correlations betweend ocking scoresa nd experimental binding affinities, suggesting the need of further refinements of the binding poseb ym eans of more extensive calculations. [40] 
Molecular DynamicSimulations
Before running the MDs imulations of the docking solutions, the MD methodw as evaluated performing a1 00 ns MD on the crystalP DE4D-Roflumilast complex1 XOQ. The stable RMSD values of the backbone of the protein and ligand,e valuated considering the RMSD value change from the startingc onformation (Figure 4) , demonstrated the suitability of the selected MD parametersf or the further simulations.
Starting from the previously selected Ac onformation, we thus performed af irst run of 80 ns MD simulations on all the five ligands-receptor complexes. Unexpectedly, while Roflumilast resulted stable in Ac onformation( Figure 4A ), for 1-5,t he docking posew as not confirmed byM Dr esults. In fact, compound 1 was unstableduring all the simulation (such shownb yR MSD value for the ligand, Figure 4B) , immediately losing the H-bond with H204 and after 40 ns the one with Q369.A sr egards compound 3, consistently with the behavior of compound 1,b oth isomers were unstable in their trajectories. Same conclusions could be detected for compounds 2 and 5.F inally even in the case of compound 4,t he catecholo xygen atoms did SPECIAL ISSUE Figure 4C) , engaging an ew H-bond between the iminoether oxygena nd Y329, whichs tabilize the compound till the end of the simulation. Notably this latter binding mode was comparable to the conformationBfrom docking calculations. In the context of the latter result and of the discussed dockings olutions, as econd MD simulation was performed for each inhibitor 1-5 starting from conformation B. In addition,s ince for all compoundsi somers R and S similarlyi nteracted with PDE4D both in docking and in the first MD simulations, the followings tudies were performed involving only S isomer.
Notably,t hese complexes resulted stable( see as example ligand 1,F igure 4D), unless the loss of the Hb ond with Q369, which was conservedd uring all the simulation only by compound 1,i nvolving its carbonyl oxygen ( Figure 5) . A detailed analysis of the key interactions for all the complexes submitted to MD was performed, considering the most representative structure for each complex, calculated from the MD trajectories applying cluster analysis where the RMSD of the complex was stable. The complexes highlighted some commonf eatures which helped us to better define the bindingm ode corresponding to conformation B.
In detail, some interactionsw ere sharedb ya ll the compounds, in particulart he van der Waals contacts with Y159, L319, N321, P322, Y329, W332, T333, I336,M 357, S368. Moreover each ligand formed an Hb ond between its iminoetherp ortion and an active site residue and definitively did not occupy the metal pocket and the solventf illed side pocket of the active site.
As written above, compound 1 ( Figure 5 ), the most potent and selective inhibitor among the data-set, wast he only able to form aw ide net of stable H-bondi nteractions, mainly in the nearby of Q369 and Y329 residues. More in detail, the carbonyl oxygen of 1,i nvolved in an H-bond with the amidic nitrogen of Q369, was engaged also in two additional water mediated H-bonds, one with Y329,a nd one againw ith Q369, supporting aw ater molecule to bridge betweent hese two residues. This pattern of interaction should be probably able to reinforce the stabilisingHbond betweenQ 369 and Y329, always observable in the PDE4D crystal structures. Af urther water mediated H-bond, performed between the morpholine oxygen and the carbonyl oxygeno fD 318 backbone, increasedt he complex stability.C ompound 2 displayed an H-bond between its carbonyl oxygen and Y329, plus a pÀp stacking interaction with F372. Concerning the remaining compounds, none of SPECIAL ISSUE them showed the same H-bondss tability of 1 and 2,t hus the following interactions were observedo nly for modest percentages of frames. Concerning compound 4,i ts conformation Bp erformed aw ater bridge mediated H-bond, between the iminoether oxygen and Y329 and the only direct H-bond presenti nt he latest 40 ns was the one with Q369 ( Figure 6 ). Compound 5 displayedasimilar pattern of interactions, with ar educedn umber of frames involvedi n water bridge H-bondsw ith Q369 and D318, plus a pÀp stacking interaction with F340. No strong and direct Hbonds interactionsw ere detecteda lso for compound 3, even if the ligand RMSD was stable and Q369 held its Hbond with Y329.
Consistently with biological data relatedt ot he analyzed compounds, the sole sub-micromolar compound 1 was the one able to form the highest number of H-bond interactionsw ith the bindings ite. This patterno fi nteraction suggested the H-bond with Q369 as the pivotal element to gain potency in PDE4 inhibition, in accordance with literature [14] ,a nd underlined the importance of the interactions with the water molecules inside the active site.
In conclusion, these computational results highlight an ew binding mode for catecholi nhibitors, conformation B, within the human PDE4D enzyme and the interaction with residue Q369,Y 329, and F340, often in combination, resulted to be essential for the complex stability.I np articular,t he ligands have been predictedt od ifferently occupy the space of the active site if compared with previous PDE4DIs, since no direct contactsw ith the metal pocket have been revealed. The great number of the interactions involveda minoa cid residues closet or esidue Q369 and the aromatic ring of their catechol moiety,a ccording to our simulations, seems oriented toward the regiono ft he active site where UCR2a nd CR3 may potentially close over.S ince the closure of these two domains is ad ynamicp rocess, the simulation of how the interaction with the studied compoundsm ay occur is not possiblew ithout the availability of acomplete PDE4 crystal structure. The preliminary observation is that the interaction with these regulatory domains may allow the selectivity of action on PDE4D amongt he other isoforms.
In Silico Model Validation
To preliminary validate conformation Ba sb inding mode for the iminoether series of PDE4D inhibitors, new docking cal-SPECIAL ISSUE culationsw ere made:t he new datasetc onsisted of our 12 reported analogues of 1 [28] (compounds 36-47,T able 6), which have been alreadyd ocked onto 1XOQ( published data) [28] .I nt he new calculationst he optimized PDE4Dc onformationw ith 1 after MD runs (theo ne discussed above), was used as enzyme model. Here the interaction with Q369 became essential to distinguish active from inactive compounds (in accordance with literature which highlighted the invariantg lutamine as the pivotal residue for PDE4Di nhibition). Indeed, docking solutionsw ith the optimized PDE4D model displayed 36-47 in conformationBand showed that the only active compoundso ft he dataset (compound 38, 40 and 41)m anagedt of orm ab i-dentate H-bond between Q369 and their iminoether portion.M oreover 38 formed an additional H-bond with D318. Notably 42-47 didn't have the iminoether group, thus preventing the formation of the H-bond with Q369, and probably affecting in this way the inhibition activity.T he pivotal role of this bi-dentate interaction may be suggested even by the inactivity of 39 which displayed an acetylateh ydroxyl group on the iminoether chain. Finally inactivec ompound 36 and 37,t he longer analogues of 1,s howed only oneHbond with Q369, since the longerc hain didn't manage to involve the carbonyl oxygen in the interaction, thus not forming an enough stable interaction with PDE4D active site. Notably,t he conformation As olutions retrieved by the reported previous dockingc alculations [28] allowed the formation of the double Q369 H-bond for all the compounds, thus explaining the difference in potency only with little different patternso fi nteractionsa tthe Mp ocketl evel. Thus, we suggest that conformation Bm ore accurately promote SAR considerations on this series of compounds, pointing out the key elements to allow PDE4 inhibition:i ) the iminoether moiety as H-bond acceptor anchor point ii) the presence of as econd polar group on the chain in the proper position to form an additional H-bond with Q369 iii) aterminal ring with polar atoms to make additional interactions with the active site. However,since the lack of acrystal PDE4D-iminoether analogue complex with UCR1, UCR2a nd CR3, the role of the aromatic ring is still to be defined.
SPECIAL ISSUE
4C onclusions
Up to now,s everal studies indicated the PDE4Di soform as an interesting targetf or neurodegenerative pathologies such as Alzheimer'sd isease. Moreover, it has been clearly demonstrated that selective PDE4Di nhibitors could improve memory and synaptic functions without undesirable side effects such as nausea and sedation. The lack of total length PDE4D crystal structure has impaired until now the rational design of new more selective compounds. On these bases, in order to deeply understand the interaction of our previously developed PDE4DIs and their enzymatic target, we have applied ac omputational study that involved docking and molecular dynamic simulations.
Any information coming from the just the dockings tudies yielded two recurring binding modes for our inhibitors (conformationA ,c onformation B). Interestingly,t he results of molecular dynamic simulations performed as as ubsequent step on our compounds 1-5 highlighted conformation Ba st he most stable,t herefore identifying the putative PDE4DIs activep ose for these data-set. Moreover the new binding mode was more consistent with the biological profile of already published compoundso ft he same series (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) , revealing the essential features for PDE4D inhibition. This result could be useful to rationally guide the design and synthesis of new potent and selective PDE4DIs in the future. 
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